1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Eurobio Scientific S.A.

Eurobio Scientific S.A.

ALERS.PA
Eurobio Scientific S.A.undefined flagEuronext Paris
22.50
EUR
-0.10
- -
226.54MMarket Cap
Eurobio Scientific S.A.
ALERS.PA
(Euronext Paris)

Recent

price

22.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
5.09
1.48
2.83
10.8
10.09
8.41
7.24
4.9
5.16
5.42
16.85
17.03
13.45
11.66
15.08
16.45
Revenue per Share
-4.68
-2.11
-3.21
-2.11
-1.77
-1.66
-1.98
-1.14
-0.28
0.29
6.56
5.58
2.2
0.43
0.39
0.47
Basic EPS, GAAP
-3.64
-1.83
-2.52
-1.92
-1.3
-0.73
-0.9
-0.16
-0.22
0.31
4.7
5.91
3.55
2.04
1.31
0.61
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.32
0.16
0.49
0.33
0.35
0.34
0.33
0.35
0.32
0.33
0.32
0.33
0.32
0.31
0.32
0.32
Book Value per Share
11.52
4.03
3.92
1.55
2.1
1.52
0.33
-0.45
-0.24
0.59
7.26
12.82
1.59
1.98
2.47
3.16
Tangible Book Value per Share
2
3
2
3
3
4
4
9
10
11
11
11
11
11
10
10
Basic Weighted Avg Shares
8
5
5
31
31
30
28
43
51
59
189
185
153
130
155
169
Sales/Revenue/Turnover
-82.85
-162.28
-128.79
-22.84
-18.18
-27.92
-26.09
-13.47
-2.3
0.96
43
37.96
20.23
7.8
6.34
6.37
Operating Margin (%)
1
1
- -
2
3
2
2
6
6
7
7
7
9
14
17
17
Depreciation Expense
-8
-7
-6
-6
-5
-6
-8
-10
-3
3
73
61
25
5
4
5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.16
15.1
15.99
30.71
36.39
37.66
Effective Tax Rate (%)
-92.04
-142.29
-113.54
-19.49
-17.54
-19.68
-27.3
-23.21
-5.48
5.34
38.91
32.78
16.34
3.72
2.59
2.89
Profit Margin (%)
25
13
8
5
14
11
2
6
8
9
87
137
91
91
48
45
Working Capital
7
- -
2
2
8
6
2
14
15
11
15
11
99
86
10
12
LT Debt
19
14
25
21
21
18
12
32
30
37
108
161
173
175
179
184
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
71.48
35.97
10.81
2.4
2.54
3.22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
257.32
225.55
37.7
7.05
10.97
34.56
Return on Capital (%)
-1,466.04
-1,315.85
-805.87
-658.68
-542.73
-514.57
-617.9
-453.55
-88.43
93.17
2,033.23
1,667.88
686.97
135.59
117.9
148.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.16%
12.58%
2.83%
Free Cash Flow
106.38%
-30.62%
-53.28%
Net Income, GAAP
185.22%
-30.53%
21.69%
Sales/Revenue/Turnover
29.43%
-1.28%
9.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
130
2024
- -
- -
- -
- -
155
2025
- -
- -
- -
- -
169

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.43
2024
- -
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.47

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
FUJIFILM Holdings Corporation (4901.T)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)
Artivion, Inc. (AORT)
Establishment Labs Holdings Inc. (ESTA)
Bonesupport Holding AB (publ) (0RQO.L)
Boston Scientific Corporation (BSX.F)
Business
Eurobio Scientific S.A. (ALERS.PA) develops, manufactures, and commercializes specialty in vitro diagnostic tests and products for clinical and research use, with a diversified portfolio spanning transplantation, infectious diseases, life sciences, and oncology. Core offerings include reagents and software for transplant matching and chimerism monitoring, culture media for cornea graft transplants, prognostic genomic tests for breast and prostate cancer, genetic molecular tests for infectious diseases, fertility, and dermatological conditions, cell culture media, quality controls, and serology products for infectious and autoimmune diseases under brands such as GenDx, GenBio, AlloMap, TQS (Tetanus Quick Stick), and EBX molecular biology family. The company also distributes third-party in vitro diagnostic products through its extensive network and provides dedicated reagents to pharmaceutical, biotechnology, and research laboratories. Headquartered in Les Ulis, in the Paris region of France, Eurobio Scientific operates production units in France, Germany, the Netherlands, and the United States, with subsidiaries and affiliates across more than 10 countries including the US (San Diego and Chicago), UK, Germany, Switzerland, Belgium, Italy, and the Netherlands. Founded in 1962, the group employs over 360 people worldwide, including 50 R&D scientists, and generates more than 30% of revenues from proprietary products it designs and produces. Recent major developments include the December 2024 takeover bid by EB Development, supported by NextStage AM and IK Partners, which secured 88.9% of the share capital to accelerate growth and external expansion in in vitro diagnostics and intelligent health markets. The company completed the acquisition of the Life Science unit of Voden Medical Instruments S.p.A. in Italy in March 2025, alongside prior strategic purchases such as GenDx in August 2022—a global leader in HLA typing for transplant compatibility—and integrations of DID Diagnostic International and Alpha Biotech. These moves, backed by NextStage AM since May 2022, strengthen proprietary product lines, management structure, and post-Covid transformation toward becoming a leading global specialty diagnostics provider.